(Reuters) – Merck has cleared a major anti-trust hurdle to its planned $17 billion (11 billion pound) acquisition of Sigma-Aldrich with the latter’s agreed sale of assets to Honeywell , the German drugmaker said on Tuesday.
Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.
“This is another key step towards completing the acquisition of Sigma-Aldrich,” Merck executive board member Bernd Reckmann said in a statement on Tuesday.
Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November.
The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction.
Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.
(Reporting by Georgina Prodhan; editing by Jason Neely)
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
